Patents by Inventor Lieven Meerpoel

Lieven Meerpoel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
    Patent number: 11001569
    Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 11, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10981926
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 20, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20210087182
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: January 20, 2017
    Publication date: March 25, 2021
    Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
  • CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20210032267
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: February 6, 2020
    Publication date: February 4, 2021
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10898504
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Brian Christopher Shook, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Tongfei Wu, Lieven Meerpoel
  • Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors
    Patent number: 10894793
    Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 19, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Olivier Alexis Georges Querolle
  • NOVEL SPIROBICYCLIC ANALOGUES
    Publication number: 20200369707
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 26, 2020
    Inventors: Jonas VERHOEVEN, Guido Alfons F. VERNIEST, Johannes Wilhelmus John F. THURING, Tongfei WU, Vineet PANDE, Lieven MEERPOEL, Dirk BREHMER, Weimei SUN, Scott E. DENMARK
  • NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200360416
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Application
    Filed: March 20, 2020
    Publication date: November 19, 2020
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200289539
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 17, 2020
    Inventors: Didier Jean-Claude BERTHELOT, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Ronaldus Arnodus Hendrika Joseph GILISSEN, Edward Charles LAWSON, Vineet PANDE, Marcus Cornells Bernardus Catbarina PARADE, Wim Bert Griet SCHEPENS, Brian Christopher SHOOK, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE, Weimei SUN, Tongfei WU, Lieven MEERPOEL
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS
    Publication number: 20200181132
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 11, 2020
    Inventors: Patrick Rene Angibaud, Olivier, Alexis Georges QUEROLLE, Didier Jean-Claude BERTHELOT, Christophe MEYER, Matthieu Philippe, Victor WILLOT, Lieven MEERPOEL, Thierry, François Alain, Jean JOUSSEAUME
  • 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10653711
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: May 19, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • PYRAZOLYL QUINOXALINE KINASE INHIBITORS
    Publication number: 20200131153
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
  • Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
    Publication number: 20200109150
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 9, 2020
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20200109129
    Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or disorders.
    Type: Application
    Filed: January 20, 2017
    Publication date: April 9, 2020
    Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Gerhard Mx GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS A PI3KB INHIBITORS
    Publication number: 20200079763
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 12, 2020
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Quinoxaline and pyridopyrazine derivatives as PI3K? inhibitors
    Patent number: 10526316
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Pyrazolyl quinoxaline kinase inhibitors
    Patent number: 10519137
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: December 31, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Steven John Woodhead, Michael Reader, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Timothy Pietro Suren Perera, Berthold Wroblowski, Alexandra Papanikos, Olivier Alexis Georges Querolle, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10501469
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS
    Publication number: 20190359598
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 28, 2019
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20190337924
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1a, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: November 7, 2019
    Inventors: Gilles Bignan, Peter J Connolly, Jan Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B Trabalón Escolar